ArticleChemistry & biodiversity2026
Unveiling the Mechanism Underlying Diyu Shengbai Tablet in Remediating Leukopenia Based on Network Pharmacology, Metabonomics, and Fecal Transcriptomics.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Therapeutic Potential of Ziyuglycosides fromDrug design, development and therapy · 2026Review
- Pathogenesis and therapeutic strategies for irritable bowel syndrome: an integrated perspective from dynamic balance theory of Chinese medicine.Frontiers in medicine · 2026Review
- Unveiling the Mechanism Underlying Diyu Shengbai Tablet in Remediating Leukopenia Based on Network Pharmacology, Metabonomics, and Fecal Transcriptomics.Chemistry & biodiversity · 2026Article
- Ziyuglycoside II ameliorates chemotherapy-induced neutropenia by promoting neutrophil differentiation and functional recovery via SPI1 and C/EBPϵ transcriptional regulation.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We aimed to integrate network pharmacology, metabonomics, and fecal transcriptomics to elucidate the mechanism of action of Diyu Shengbai Tablets (DST) in leukopenia treatment. Key bioactive components and core targets of DST in leukopenia were identified using network pharmacology. Spleen metabonomics, fecal transcriptomics, and MetOrigin analysis were employed to investigate potential mechanisms. Molecular docking, molecular dynamics simulations, and enzyme-linked immunosorbent assay were performed to validate findings. Network pharmacology predicted Hypericin and Quercetin-3-galactoside-7-glucoside as major active constituents of DST. metabonomic analysis identified alterations in 133 differential metabolites in the spleen, with linoleic acid metabolism as the primary affected pathway. 16S rRNA sequencing indicated normalization of Lactobacillus abundance. Molecular docking and dynamics simulations showed low binding free energies between active compounds (e.g., Hypericin) and targets such as PIK3CA and SRC. Serum levels of Mouse interleukin-6 and Granulocyte colony-stimulating factor were elevated following DST intervention. DST modulates spleen metabolic profiles in leukopenic mice, restores gut microbial composition, and exerts therapeutic effects by regulating linoleic acid metabolism and influencing the PI3K-Akt signaling pathway. These findings provide a foundation for further exploration of multi-target mechanisms in traditional Chinese medicine for leukopenia management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.